A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
This study is a two-part trial consisting of Part A (presented in this record) and Part B (see NCT02047734).
The primary objective in Part A of this study was to demonstrate the superior efficacy of ozanimod compared to placebo by showing a reduction in the cumulative number of total gadolinium-enhancing (GdE) lesions from Week 12 to Week 24 in patients with relapsing multiple sclerosis (RMS).
Inclusion Criteria:
Exclusion Criteria:
Cantania, 95123, Italy
Konstancin-Jeziorna, 05-510, Poland
Lódzkie, 90-324, Poland
Plewiska, 62-064, Poland
Podlaskie, 15-402, Poland
Poznan, 61-853, Poland
Warminsko-mazurskie, 10-443, Poland
Chernihiv, 14033, Ukraine
Dnipropetrovsk, 49027, Ukraine
Kharkiv, 61103, Ukraine